Lazard Asset Management
ASMB icon

Lazard Asset Management’s Assembly Biosciences ASMB Stock Holding History

Lazard Asset Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71
Closed -$1K – 2278
2024
Q3 		$1K Buy
+71
New +$1.08K ﹤0.01% 2119

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Lazard Asset Management's ASMB Position: Q4 2024 in Review

Lazard Asset Management sold out of Assembly Biosciences (ASMB) in Q4 2024, closing a stake of 71 shares — an estimated $1K sold.

Lazard Asset Management first reported a position in ASMB in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 35 funds tracked by Wall St. Rank hold ASMB as of Q4 2024.

  • Lazard Asset Management reported no remaining Assembly Biosciences position as of Q4 2024 after selling out during the quarter.
  • Lazard Asset Management sold 71 Assembly Biosciences shares in Q4 2024, an estimated $1K.
  • Lazard Asset Management first reported a position in Assembly Biosciences in Q3 2024 and held it in 1 quarter.
  • Lazard Asset Management's Assembly Biosciences position peaked at $1K in Q3 2024.
  • 35 funds tracked by Wall St. Rank held Assembly Biosciences as of Q4 2024.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.